Keith Henry

11.2k citations

135 papers · 7.6k · 3 hit papers · h-index 49

Impact in

Virology top 0.1%
- HIV Research and Treatment
Infectious Diseases top 0.2%
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions

Papers in

Infectious Diseases 75
- HIV/AIDS drug development and treatment 46
- HIV/AIDS Research and Interventions 36
Virology 43
- HIV Research and Treatment 43

Co-authors: Henry H. Balfour (12 shared papers)Alejo Erice (11 shared papers)Winston Cavert (6 shared papers)Courtney V. Fletcher (9 shared papers)Ashley T. Haase (5 shared papers)Zhi‐Qiang Zhang (4 shared papers)Kristin Gebhard (4 shared papers)Mary Zupancic (3 shared papers)
Journals: The Journal of Infectious Diseases (11 papers)AIDS (9 papers)Sexually Transmitted Diseases (6 papers)JAMA (6 papers)JAIDS Journal of Acquired Immune Deficiency Syndromes (6 papers)
Partner nations: United States United Kingdom Germany

In The Last Decade

Keith Henry

133 papers receiving 7.2k citations

Keith Henry's Hit Papers

align trajectories log scale

Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America 2003 · 750 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2003 New England Journal of Medicine
1997 Science
1996 Science

Peers

Countries citing papers authored by Keith Henry

Since Specialization

Citations

This map shows the geographic impact of Keith Henry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keith Henry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keith Henry more than expected).

Fields of papers citing papers by Keith Henry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keith Henry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keith Henry. The network helps show where Keith Henry may publish in the future.

Co-authors

The 25 scholars most cited alongside Keith Henry, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Keith Henry Line = papers co-authored together Keith Henry links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 135 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America New England Journal of Medicine ·Jacob Lalezari, Keith Henry, Mary O’Hearn, Joan Montaner, Peter J. Piliero, Benoît Trottier, Sharon Walmsley, Calvin Cohen, Daniel R. Kuritzkes, Joseph J. Eron, Jain Chung, Ralph DeMasi, Lucille Donatacci, Claude Drobnes, John Delehanty, Miklos Salgo Hit paper breakdown →	2003	750
2	Kinetics of Response in Lymphoid Tissues to Antiretroviral Therapy of HIV-1 Infection Science ·Winston Cavert, Daan W. Notermans, Katherine Staskus, Stephen W. Wietgrefe, Mary Zupancic, Kristin Gebhard, Keith Henry, Zhi‐Qiang Zhang, Roger Mills, Hugh McDade, Jaap Goudsmit, Sven A. Danner, Ashley T. Haase Hit paper breakdown →	1997	542
3	Quantitative Image Analysis of HIV-1 Infection in Lymphoid Tissue Science ·Ashley T. Haase, Keith Henry, Mary Zupancic, Gerald Sedgewick, Russell A. Faust, Holly Melroe, Winston Cavert, Kristin Gebhard, Katherine Staskus, Zhi‐Qiang Zhang, Peter J. Dailey, Henry H. Balfour, Alejo Erice, Alan S. Perelson Hit paper breakdown →	1996	513
4	Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial The Lancet ·Edwin DeJesus, Jürgen K. Rockstroh, Keith Henry, Jean‐Michel Molina, Joseph Gathe, S. Ramanathan, Xuelian Wei, Kitty Yale, Javier Szwarcberg, Kirsten White, Andrew Cheng, Brian P. Kearney	2012	277
5	Primary Infection with Zidovudine-Resistant Human Immunodeficiency Virus Type 1 New England Journal of Medicine ·Alejo Erice, Douglas L. Mayers, David G. Strike, Kim Sannerud, Francine E. McCutchan, Keith Henry, Henry H. Balfour	1993	201
6	Kinetics of CD4+ T cell repopulation of lymphoid tissues after treatment of HIV-1 infection Proceedings of the National Academy of Sciences ·Zhi‐Qiang Zhang, Daan W. Notermans, Gerald Sedgewick, Winston Cavert, Stephen W. Wietgrefe, Mary Zupancic, Kristin Gebhard, Keith Henry, Lawrence R. Boies, Zongming Chen, Marc K. Jenkins, Roger Mills, Hugh McDade, Carolyn Goodwin, Caspar M. Schuwirth, Sven A. Danner, Ashley T. Haase	1998	189
7	Use of Intravitreal Ganciclovir (Dihydroxy Propoxymethyl Guanine) for Cytomegalovirus Retinitis in a Patient With AIDS American Journal of Ophthalmology ·Keith Henry, Herbert L. Cantrill, Courtney V. Fletcher, Barbara J. Chinnock, Henry H. Balfour	1987	164
8	Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study The Lancet HIV ·Jean‐Michel Molina, Bonaventura Clotet, Jan van Lunzen, Adriano Lazzarin, Matthias Cavassini, Keith Henry, Valeriv Kulagin, Naomi Givens, Carlos Fernando de Oliveira, Clare Brennan	2015	159
9	Treatment of Cytomegalovirus Retinitis with Intravitreal Ganciclovir Ophthalmology ·Herbert L. Cantrill, Keith Henry, N. Holly Melroe, William H. Knobloch, Robert C. Ramsay, Henry H. Balfour	1989	151
10	Indinavir Concentrations and Antiviral Effect Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·Edward P. Acosta, Keith Henry, Leslie Baken, Linda M. Page, Courtney V. Fletcher	1999	148
11	Chs1 of Candida albicans is an essential chitin synthase required for synthesis of the septum and for cell integrity Molecular Microbiology ·Carol A. Munro, (unknown), Arlene Buchan, Keith Henry, Jeffrey M. Becker, Alistair J. P. Brown, Christine Bulawa, Neil A.R. Gow	2001	140
12	Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir AIDS ·Pablo Tebas, Amy K. Patick, Ellen Kane, Michael K. Klebert, Janet H. Simpson, Alejo Erice, William G. Powderly, Keith Henry	1999	140
13	High Prevalence of Echocardiographic Abnormalities among HIV-infected Persons in the Era of Highly Active Antiretroviral Therapy Clinical Infectious Diseases ·Kristin Mondy, John S. Gottdiener, Edgar T. Overton, Keith Henry, Timothy J. Bush, Lois Conley, John Hammer, Charles C. J. Carpenter, Erna M. Kojic, Payal T. Patel, J. T. Brooks, (unknown)	2010	135
14	Blockade of HERG channels by HIV protease inhibitors The Lancet ·Blake D. Anson, Joel Weaver, Michael J. Ackerman, Omobosola Akinsete, Keith Henry, Craig T. January, Andrew D. Badley	2005	131
15	Concentration-controlled compared with conventional antiretroviral therapy for HIV infection AIDS ·Courtney V. Fletcher, Peter L. Anderson, Thomas N. Kakuda, Timothy W. Schacker, Keith Henry, Cynthia R. Gross, Richard C. Brundage	2002	120
16	Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy AIDS ·Richard W. Price, Constantin T. Yiannoutsos, David B. Clifford, Lawrence Zaborski, Alex Tselis, John J. Sidtis, Bruce A. Cohen, Colin D. Hall, Alejo Erice, Keith Henry	1999	119
17	Poor Initial CD4+ Recovery With Antiretroviral Therapy Prolongs Immune Depletion and Increases Risk for AIDS and Non-AIDS Diseases JAIDS Journal of Acquired Immune Deficiency Syndromes ·Jason V. Baker, Grace Peng, Joshua Rapkin, David Krason, Cavan Reilly, Winston Cavert, Donald I. Abrams, Rodger D. MacArthur, Keith Henry, James D. Neaton	2008	116
18	Risk of cancers during interrupted antiretroviral therapy in the SMART study AIDS ·Michael J. Silverberg, Jacqueline Neuhaus, Mark Bower, Daniela Gey, Angelos Hatzakis, Keith Henry, José A. Hidalgo, Leonardo Lourtau, James D. Neaton, Giuseppe Tambussi, Donald I. Abrams	2007	109
19	A Randomized, Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Coformulated Emtricitabine and Tenofovir DF for Initial Treatment of HIV-1 Infection JAIDS Journal of Acquired Immune Deficiency Syndromes ·Jürgen K. Rockstroh, Edwin DeJesus, Keith Henry, Jean‐Michel Molina, Joseph Gathe, S. Ramanathan, Xuelian Wei, Andrew Plummer, Michael E. Abram, Andrew Cheng, Marshall W. Fordyce, Javier Szwarcberg	2013	101
20	Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults AIDS ·Calvin Cohen, David A. Wohl, José Ramón Arribas, Keith Henry, Jan van Lunzen, Mark Bloch, William Towner, Edmund Wilkins, Ramin Ebrahimi, Danielle Porter, Kirsten White, Ivan Walker, Susan K. Chuck, Shampa De-Oertel, Todd Fralich	2014	95

About Keith Henry

Keith Henry is a scholar working on Infectious Diseases, Virology, Epidemiology, Emergency Medicine and Molecular Biology, having authored 135 papers that have together received 7.6k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (46 papers), HIV Research and Treatment (43 papers), HIV/AIDS Research and Interventions (36 papers), HIV-related health complications and treatments (22 papers), HIV, Drug Use, Sexual Risk (10 papers), Pneumocystis jirovecii pneumonia detection and treatment (9 papers), Cervical Cancer and HPV Research (6 papers) and Adolescent Sexual and Reproductive Health (6 papers). The work is most often cited by research in Virology (3.2k citations), Infectious Diseases (3.9k citations), Emergency Medicine (1.2k citations), Epidemiology (1.6k citations) and Immunology (781 citations). Keith Henry has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Henry H. Balfour, Alejo Erice, Winston Cavert, Courtney V. Fletcher, Ashley T. Haase, Zhi‐Qiang Zhang, Kristin Gebhard, Mary Zupancic, Katherine Staskus and Herbert L. Cantrill. Their work appears in journals such as The Journal of Infectious Diseases, AIDS, Sexually Transmitted Diseases, JAMA and JAIDS Journal of Acquired Immune Deficiency Syndromes.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Keith Henry

Impact in

Papers in i

In The Last Decade

Keith Henry

Keith Henry's Hit Papers

Peers

Countries citing papers authored by Keith Henry

Fields of papers citing papers by Keith Henry

All Works

About Keith Henry

Explore authors with similar magnitude of impact

Papers in